Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by Kovack Advisors Inc.

Kovack Advisors Inc. lifted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 10.8% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,388 shares of the medical equipment provider’s stock after purchasing an additional 135 shares during the period. Kovack Advisors Inc.’s holdings in Intuitive Surgical were worth $682,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. Hazlett Burt & Watson Inc. raised its position in Intuitive Surgical by 5.8% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider’s stock valued at $177,000 after purchasing an additional 20 shares during the last quarter. Mitchell Mcleod Pugh & Williams Inc. boosted its position in shares of Intuitive Surgical by 4.1% during the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider’s stock worth $247,000 after purchasing an additional 20 shares in the last quarter. Ullmann Wealth Partners Group LLC increased its position in shares of Intuitive Surgical by 1.6% in the 3rd quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider’s stock valued at $653,000 after buying an additional 21 shares in the last quarter. One Wealth Management Investment & Advisory Services LLC raised its stake in Intuitive Surgical by 3.4% during the 2nd quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock worth $310,000 after buying an additional 23 shares during the period. Finally, Falcon Wealth Planning grew its stake in Intuitive Surgical by 0.4% in the third quarter. Falcon Wealth Planning now owns 5,693 shares of the medical equipment provider’s stock valued at $2,797,000 after acquiring an additional 23 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Trading Down 0.1 %

Shares of NASDAQ:ISRG opened at $536.69 on Thursday. The company’s 50 day moving average is $495.85 and its 200 day moving average is $455.08. The company has a market cap of $191.16 billion, a PE ratio of 86.28, a price-to-earnings-growth ratio of 5.28 and a beta of 1.39. Intuitive Surgical, Inc. has a twelve month low of $287.98 and a twelve month high of $542.59.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, topping the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The firm had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Equities research analysts predict that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Gary S. Guthart sold 18,151 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the transaction, the chief executive officer now owns 24,219 shares in the company, valued at $12,391,166.97. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CEO Gary S. Guthart sold 18,151 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the sale, the chief executive officer now owns 24,219 shares of the company’s stock, valued at approximately $12,391,166.97. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Amy L. Ladd sold 450 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the sale, the director now owns 821 shares in the company, valued at $402,519.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 91,178 shares of company stock worth $45,897,071. 0.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ISRG has been the subject of a number of analyst reports. Citigroup lifted their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Leerink Partners increased their price objective on shares of Intuitive Surgical from $489.00 to $502.00 in a research note on Thursday, October 17th. Piper Sandler reiterated an “overweight” rating and set a $538.00 price objective (up from $495.00) on shares of Intuitive Surgical in a research report on Friday, October 18th. Oppenheimer reaffirmed a “market perform” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. Finally, Royal Bank of Canada lifted their price objective on Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a research report on Friday, October 18th. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $513.74.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.